Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Clinical trial results from MASCOT Trial evaluating AngioSculpt PTA Scoring Balloon Catheter announced

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today favorable clinical trial results from the MASCOT Trial, an important study evaluating the AngioSculpt® PTA Scoring Balloon Catheter for the treatment of femoro-popliteal PAD (peripheral artery disease).

15 Mar 2010

U.S. prescribing information for PLAVIX revised

Sanofi-aventis U.S. and Bristol-Myers Squibb Company today announced revisions to the U.S. prescribing information for PLAVIX® (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite.

15 Mar 2010

Researchers develop Intermountain Risk Score tool to assess patients' health

Researchers from the Heart Institute at Intermountain Medical Center in Murray, Utah, have devised a better way to determine an individual's risk for problems, such as heart attack and heart failure, according to a new study.

15 Mar 2010

Data shows increased risk of heart attack, stroke for patients having high blood pressure

For patients with diabetes and heart disease, less isn't always more - at least when it comes to blood pressure.

15 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

Lowering blood pressure to normal levels - below currently recommended levels - did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular disease events, according to new results from the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial.

15 Mar 2010

New study finds green tea extract may prevent Alzheimer's disease and dementia

Long known to be beneficial in heart disease, diabetes and some cancers, a new study finds a specific green tea extract may delay or prevent Alzheimer's disease and dementia. A. Holliday & Company's "Teawell 50," is a 50 percent pure extraction of EGCG (epigallocatechin gallate) – a flavonoid which is the most potent of four major catechins in green tea.

15 Mar 2010

FDA warns patients and physicians about the efficacy of Plavix treatment

The U.S. Food and Drug Administration today added a boxed warning to the anti-blood clotting drug Plavix (clopidogrel), alerting patients and health care professionals that the drug can be less effective in people who cannot metabolize the drug to convert it to its active form.

15 Mar 2010

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).

15 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

Cytori Therapeutics reports total revenues of $14.7M for 2009

Cytori Therapeutics is reporting its financial results for the year ended December 31, 2009.

From Evident Corporation - Life Sciences 12 Mar 2010

Study shows experimental thyroid drug reduces cholesterol

An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

12 Mar 2010

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new VivoTag® 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.

12 Mar 2010

Hamilton Health Sciences establishes new research facility

Hamilton's role as one of the world's leading centres in cardiac, vascular and stroke research was amplified today with the grand opening of the David Braley Cardiac, Vascular and Stroke Research Institute at the Hamilton General Hospital site of Hamilton Health Sciences.

12 Mar 2010

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Only half of all patients at high risk of heart disease are given correct targets for lowering their cholesterol levels according to a study of 25,250 patients in Germany published online today (Thursday 11 March) in the European Heart Journal.

11 Mar 2010

Lotus Pharmaceuticals announces groundbreaking ceremony to construct new building complex in Beijing

Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China, reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.

11 Mar 2010

Poor, minority adults with chronic kidney disease face increase risk of developing ESRD

Chronic kidney disease (CKD) afflicts a large number of younger minority adults receiving medical care in settings that serve the uninsured and underinsured (settings collectively known as the healthcare safety net). Poor, minority adults with moderate to severe CKD are also two to four times more likely to progress to kidney failure than non-Hispanic whites.

11 Mar 2010

Adherence to lipid-lowering guidelines may help reduce cardiovascular deaths

11 Mar 2010

Eureka Genomics announces closing of $3.7M private financing round

Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics’ high-throughput sequencing and bioinformatics service business on a global basis.

11 Mar 2010

Small study shows eprotirome decreases LDL cholesterol

People whose "bad" cholesterol and risk of future heart disease stay too high despite cholesterol-lowering statin therapy can safely lower it by adding a drug that mimics the action of thyroid hormone. In a report published in the Mar. 11, issue of the New England Journal of Medicine, Johns Hopkins and Swedish researchers say an experimental drug called eprotirome lowered cholesterol up to 32 percent in those already on statins, an effect equal to that expected from doubling the statin drug doses, without harmful side effects.

10 Mar 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Clinical trial results from MASCOT Trial evaluating AngioSculpt PTA Scoring Balloon Catheter announced

U.S. prescribing information for PLAVIX revised

Researchers develop Intermountain Risk Score tool to assess patients' health

Data shows increased risk of heart attack, stroke for patients having high blood pressure

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

Combination therapy does not reduce cardiovascular risk in type 2 diabetes patients

New study finds green tea extract may prevent Alzheimer's disease and dementia

FDA warns patients and physicians about the efficacy of Plavix treatment

ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

Cytori Therapeutics reports total revenues of $14.7M for 2009

Study shows experimental thyroid drug reduces cholesterol

VisEn Medical introduces VivoTag 680 XL fluorescent dye for labeling biomolecules

Hamilton Health Sciences establishes new research facility

Following existing cholesterol-lowering target guidelines can prevent more heart disease-related incidents

Lotus Pharmaceuticals announces groundbreaking ceremony to construct new building complex in Beijing

Poor, minority adults with chronic kidney disease face increase risk of developing ESRD

Adherence to lipid-lowering guidelines may help reduce cardiovascular deaths

Eureka Genomics announces closing of $3.7M private financing round

Small study shows eprotirome decreases LDL cholesterol

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Newsletters you may be interested in